Ionis grants Recordati rights to zilganersen for Alexander disease

​Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.

The post Ionis grants Recordati rights to zilganersen for Alexander disease appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.